Single-center experience on renal transplantation in primary focal and segmental glomerulosclerosis using hematopoietic stem cell transplantation in thymus, bone marrow, portal and peripheral circulation

• Published in: Saudi journal of kidney diseases and transplantation 2013, Vol.24 (1), p.15-21
• Main Authors: Patel, Rashmi D., Modi, Pranjal R., Davi, Shruti D., Singhai, Atin M., Shah, Veena R., Shah, Pankaj R., Shankar, V., Trivedi, Hargovind L., Vanikar, Aruna V., Trivedi, Varsha B., Kanodia, Kamal V.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Biopsy; Bone Marrow - surgery; Care and treatment; Causes of; Chronic kidney failure; Diseases; Female; Follow-Up Studies; Glomerulosclerosis, Focal Segmental - pathology; Glomerulosclerosis, Focal Segmental - surgery; Graft Rejection - prevention & control; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic stem cells; Humans; Injections; Kidney - pathology; Kidney Transplantation - methods; Kidneys; Male; Middle Aged; Patient outcomes; Portal System - surgery; Relapse; Retrospective Studies; Secondary Prevention; Stem cells; Thymus Gland - surgery; Transplantation; Transplantation Chimera; Treatment Outcome; Young Adult; الخلايا الجذعية; الزعتر; الكلى; المتلازمة الكلوية; خلايا الدم; زرع الأعضاء; نخاع العظم
• ISSN: 1319-2442; 2320-3838
• DOI: 10.4103/1319-2442.106232

Recurrence of primary focal segmental glomerulosclerosis (FSGS) is an important cause of graft loss after renal transplantation (RTx). We report our experience in 34 patients with primary FSGS who underwent RTx between April 1999 and June 2009, using hematopoietic stem cell transplantation (HSCT). They belonged to four groups : group 1 (n = 12) received high-dose HSCT in periphery, thymus, bone-marrow, and portal circulation with low-dose non-myeloablative conditioning ; group 2 (n = 7) was modified with HSCT without marrow / thymic infusion ; and group 3 (n = 3) received HSCT and proteasome inhibitor Bortezomib replacing conditioning. Group 4 (n = 12), were controls who opted for RTx under standard triple-drug immunosuppression. Patient / donor demographics were comparable in all. No recurrence was noted in group 1 with mean follow-up of 8.1 years, whereas 28.6 % of group 2, 33.3 % of group 3, and 36.4 % of group 4 had recurrence over mean followup of 2.6, 1.1, and 6.5 years, respectively. Mean serum creatinine was 1.62, 1.69, 1.41, and 1.73 mg %, respectively. Rejections were noted in 41.7 %, 28.6 %, 0 %, and 45.5 % grafts, respectively. Groups 1 and 4 had 25 % patient loss each, group 2 had 28.6 % loss, and no loss was observed in group 3. Graft loss was noted in 33.3 % in group 1, 14.3 % in group 2, nil in group 3, and 16.7 % in the last group. Recurrent FSGS was prevented in RTx with HSCT in thymic, marrow infusion under low-dose nonmyeloablative conditioning compared to controls and Bortezomib group, thus suggesting potential role of central tolerance in FSGS.